Current Research Studies
A Phase 1 Study of FOLR1 CAR T for Pediatric Patients with FOLR1/CBFA2T3::GLIS2+ Relapsed or Refractory AML
FOLR1 CAR T
- Condition(s): Myeloid and Monocytic Leukemia
- Phase: I
- Clinicaltrials.gov ID: NCT06609928
What is the goal of the study?
This phase 1, open-label, non-randomized study will enroll pediatric patients with relapsed or refractory FOLR1+ acute myeloid leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express FOLR1 CAR.
Who can participate in the study?
Please contact the study team listed below to learn more.
Study Team:
- PI (Study Doctor): Katherine Tarlock
- Study Team Member: HemOnc CRAs, [email protected]